<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231085</url>
  </required_header>
  <id_info>
    <org_study_id>9769</org_study_id>
    <secondary_id>2016-005065-31</secondary_id>
    <nct_id>NCT03231085</nct_id>
  </id_info>
  <brief_title>Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child</brief_title>
  <acronym>IRON KID</acronym>
  <official_title>Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral iron is commonly used in conjunction with EPO preoperatively for hemorrhagic surgeries
      in children and especially in the surgery of craniosynostosis. The bioavailability of oral
      iron is low and compliance with treatment is inconsistent. The aim of this study is to
      evaluate whether the use of ferric carboxymaltose by injection, which has a much better
      bioavailability, would make it possible to increase the preoperative hemoglobin level more
      effectively and thus reduce the risk of perioperative blood transfusion .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective study, randomized in two parallel groups (martial treatment versus venous
      injection) and stratified by center (Montpellier, Nice).

      The number of subjects required is 50 patients, or 25 per group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preoperative hemoglobin</measure>
    <time_frame>day before surgery</time_frame>
    <description>Preoperative hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of patients transfused</measure>
    <time_frame>within 3 days post operative</time_frame>
    <description>The number of patients transfused and the quantity in ml / kg of transfused</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Craniosynostosis</condition>
  <arm_group>
    <arm_group_label>Fumafer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The oral treatment should begin 21 days before surgery.
Recommended Dosage according to the SPC in force:
5 to 8 kg: 2 cd rases / d or 200mg of ferrous fumarate
8 to 10 kg: 3 cd rases / d or 300mg of ferrous fumarate
10 to 12kg: 4 cd rases / d or 400mg of ferrous fumarate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The single intravenous treatment the day of the inclusion. Dosage according to: 15mg / kg iron (to dilute in 3 ml / kg of Nacl 0.9% (SSI), to pass in 15 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferrous fumarate</intervention_name>
    <description>Young children operated with craniosynostosis and treated with EPO and ferrous fumarate per os or intravenous ferric carboxymaltose.</description>
    <arm_group_label>Fumafer</arm_group_label>
    <arm_group_label>Ferinject</arm_group_label>
    <other_name>Intravenous ferric carboxymaltose.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Craniosynostosis Surgery

          -  Age: between 4 and 24 months inclusive

          -  Weight: less than 12kg

          -  Hemoglobin: 10 g / dl ≤ Hb 14 ≤ g / dl

          -  Affiliated patients or beneficiaries of a Social Security scheme

          -  Signature of the consent of the patient's parents

        Exclusion Criteria:

          -  Generalized infection

          -  Time for consultation of anesthesia with respect to the date of surgery greater than 5
             weeks or less than 22 days.

          -  Initial biological assessment dating more than 3 months before the consultation of
             anesthesia

          -  Parents do not understand French

          -  BMI greater than 20 kg.m-2

          -  Contraindications to EPO
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>24 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe PIRAT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department d'Anesthésie reanimation Lapeyronie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe PIRAT, MD</last_name>
    <phone>0467338256</phone>
    <email>p-pirat@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Bringuier, PharmaD</last_name>
      <phone>0467338256</phone>
      <email>s-bringuierbranchereau@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Craniosynostosis</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>iron peros</keyword>
  <keyword>iron intravenous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Craniosynostoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Ferrous fumarate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

